Publications
Access to testing and treatment in Europe
Written by Prof. Mojca Maticic, MD, PhD. Internal medicine & ID specialist, Head, Dpt for Viral Hepatitis, Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Slovenia
Written by Prof. Mojca Maticic, MD, PhD. Internal medicine & ID specialist, Head, Dpt for Viral Hepatitis, Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Slovenia
Declaration on the importance of civil society involvement to eliminate hepatitis C
This is a historic moment for hepatitis C treatment. With the advent of direct-acting antivirals (DAAs) we can now massively reduce the harm from an infectious disease that affects millions of people and causes hundreds of thousands of unnecessary deaths every year.
This is a historic moment for hepatitis C treatment. With the advent of direct-acting antivirals (DAAs) we can now massively reduce the harm from an infectious disease that affects millions of people and causes hundreds of thousands of unnecessary deaths every year.
EMCDDA Strategy 2025
This strategy sets out an ambitious course of travel for the agency to 2025. It presents a vision to contribute to a healthier and more secure Europe, through better informed drug policy and action.
This strategy sets out an ambitious course of travel for the agency to 2025. It presents a vision to contribute to a healthier and more secure Europe, through better informed drug policy and action.
4 things reporters get terribly wrong about "new" drugs
Much of the coverage of drugs contains misinformation and inaccurate or misleading terminology. This all serves to perpetuate unfounded myths and unhelpful hysteria about these substances.
Much of the coverage of drugs contains misinformation and inaccurate or misleading terminology. This all serves to perpetuate unfounded myths and unhelpful hysteria about these substances.
Harm reduction should address the specific needs of couples who inject drugs
Programmes usually address individuals but most equipment sharing occurs between sexual partners.
Programmes usually address individuals but most equipment sharing occurs between sexual partners.
HepScot's top ten hints for 2017
As 2017 moved forward, Hepatitis Scotland wrote ten key challenges for the year ahead.
As 2017 moved forward, Hepatitis Scotland wrote ten key challenges for the year ahead.
2016 hep-CORE Report: Monitoring European policy responses to viral hepatitis
Written by Prof Jeffrey V. Lazarus. Associated Researcher, ISGlobal, Hospital Clínic, University of Barcelona, CHIP, Rigshospitalet, University of Copenhagen, WHO Collaborating Centre on HIV and Viral Hepatitis Editor-in-Chief, Hepatology, Medicine and Policy.
Written by Prof Jeffrey V. Lazarus. Associated Researcher, ISGlobal, Hospital Clínic, University of Barcelona, CHIP, Rigshospitalet, University of Copenhagen, WHO Collaborating Centre on HIV and Viral Hepatitis Editor-in-Chief, Hepatology, Medicine and Policy.
Results of US research suggest all people with chronic HCV need treatment to reduce mortality risk
All people with chronic HCV infection should start therapy with direct-acting antivirals, research published in the online edition of Clinical Infectious Diseases suggests.
All people with chronic HCV infection should start therapy with direct-acting antivirals, research published in the online edition of Clinical Infectious Diseases suggests.
Higher incidence of HCV in females compared to males who inject drugs
Women who inject drugs have been shown to have higher incidence of HIV and risk behaviours than men, but there are conflicting reports about hepatitis C virus (HCV) incidence.
Women who inject drugs have been shown to have higher incidence of HIV and risk behaviours than men, but there are conflicting reports about hepatitis C virus (HCV) incidence.
Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review
The purpose of this review is to summarize published literature on the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection.
The purpose of this review is to summarize published literature on the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection.
